On March 12, 2024 Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, reported new data being presented on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, and hereditary cancer test, Empower, at the 2024 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer taking place March 16-18, 2024 (Press release, Natera, MAR 12, 2024, View Source [SID1234641088]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A total of seven abstracts will be presented, including two oral presentations and five poster presentations. The presentations will feature new data highlighting Signatera’s predictive and prognostic utility in ovarian cancer and other gynecologic malignancies.

"On the heels of receiving Medicare coverage for Signatera in ovarian cancer and for breast cancer in the neoadjuvant setting, we are thrilled to share new Signatera and Empower data with the gynecologic oncology community," said Adam ElNaggar, MD, medical director of oncology at Natera. "We believe this momentum is indicative of the growing clinical value our tests provide for patients across the continuum of gynecologic cancer care, and demonstrate our continued leadership in MRD."

Below is the full list of Signatera and Empower data presentations at the SGO Annual Meeting.

Oral Presentations:

Focused Plenary I: The Science to Drive Purpose | March 16, 2:15 – 3:30 PM | Presenter: Anne Knisely, MD | Ovarian Cancer
Prognostic implications of minimal residual disease detection by second look laparoscopy and circulating tumor DNA (ctDNA) in patients with ovarian cancer after frontline therapy
Focused Plenary IV: ctDNA: Molecular Mirrors & Markers | March 17, 1:45 – 2:45 PM | Presenter: Mike Shalamov | Gynecologic Cancers
Utility of ctDNA as an early predictive biomarker of response to radiation in gynecologic malignancies
Poster Presentations:

Poster #1241 | Session 1 | March 17, 1:15 – 2:45 PM | Presenter: Michael Toboni, MD | Ovarian Cancer
PARPi response monitoring using personalized ctDNA testing in patients with ovarian cancer
Poster #1242 | Session 1 | March 17, 1:15 – 2:45 PM | Presenter: Peter W. Ketch, MD | Uterine Cancer
Treatment Monitoring Utilizing ctDNA-based MRD Detection in Early Stage Uterine Cancer
Poster #1243 | Session 1 | March 17, 1:15 – 2:45 PM | Presenter: Michael Toboni, MD | Uterine Cancer
Personalized ctDNA analysis used for ctDNA detection and response monitoring in patients with advanced or recurrent uterine cancer
Poster #1274 | Session 1 | March 17, 1:15 – 2:45 PM | Presenter: Floortje Backes, MD | Endometrial and Ovarian Cancer
Utility of ctDNA in assessment of treatment response in patients with Recurrent/Metastatic Endometrial Cancer and Recurrent/Platinum-Resistant Ovarian Cancer
Poster #1181 | Session 1 | March 17, 1:15 – 2:45 PM | Presenter: Sarah Lee, MD | Pan-cancer
Diagnostic yield and characteristics of germline-positive genetic testing ordered by obstetricians and gynecologists in female patients with a personal history of cancer
About Signatera

Signatera is a personalized, tumor-informed, molecular residual disease test for patients previously diagnosed with cancer. Custom-built for each individual, Signatera uses circulating tumor DNA to detect and quantify cancer left in the body, identify recurrence earlier than standard of care tools, and help optimize treatment decisions. The test is available for clinical and research use and is covered by Medicare for patients with colorectal cancer, breast cancer, ovarian cancer and muscle invasive bladder cancer, as well as for immunotherapy monitoring of any solid tumor. Signatera has been clinically validated across multiple cancer types and indications, with published evidence in more than 50 peer-reviewed papers.